Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

PBD Biotech to discuss Actiphage® test at first AberTB Conference

Date: 17 September 2019

Bovine TB (bTB) is the most pressing animal health challenge facing Wales today, said the Rural Affairs Minister Lesley Griffiths AM upon announcing the opening of the Centre of Excellence for Bovine TB in Aberystwyth last October. Now, PBD Biotech has been invited to share its experiences at the Centre’s inaugural AberTB conference on 17 September.
cow

Bringing together international expertise with the aim of eradicating bTB, Aberystwyth University has established the Centre of Excellence for Bovine Tuberculosis as part of the Sêr Cymru programme funded by the European Regional Development Fund and Welsh Government. It is headed up by world-renowned bTB expert Professor Glyn Hewinson, Sêr Cymru Chair.

As part of this initiative, the Centre is to hold an annual TB conference (AberTB) to provide delegates with the latest information on various aspects of disease control through a series of presentations and panel discussions.

Update on key areas of TB diagnosis

Commenting on the conference, Professor Hewinson said: “Part of the mission of the Centre of Excellence is to develop further pan-industry awareness of developments within the field of Bovine TB and efforts to control this highly damaging disease.

“We will hear contributions from many highly respected individuals who can update us on all the key areas of work in TB diagnosis.

“The intention of this event is to promote a common understanding around how current practices along with developments in this field can enhance and influence work by farmers, vets, scientific researchers and government in order to progress our battle with Bovine TB.

“I am aware of the interest that has been generated in the Actiphage® test and was keen for the delegates to understand the plans that PDP Biotech have to validate their test and what timescale they have for achieving OIE test accreditation as these are a questions that are regularly raised.”

The day will focus on ‘Diagnosis of Bovine Tuberculosis: Current practice and Future Innovations’ for which Dr Ben Swift, PBD Biotech’s R&D Director, has been asked to discuss the company’s Actiphage test.

Dr Swift explains: “By identifying cattle carrying low levels of live Mycobacterium bovis, Actiphage can give farmers, vets and other animal health experts a much-needed head-start on the race to catch TB, helping to inform an effective disease management strategy.”

The test has been used successfully for disease management. As part of a private TB eradication strategy, a Devon vet helped to clear a dairy herd of bovine TB for the first time in six years.

In May 2018, the UK Government accepted Actiphage as part of their protocol for exceptional private use on TB-stricken cattle herds in England.

First Welsh farm-trial of Actiphage test

A farm-based trial is also underway in Ceredigion on a chronic breakdown dairy unit. The trial, licensed by the Welsh Government, is the first of its kind in Wales.

It is being led by Clinical Director of Tysul Vets, Robert Price-Jones, and is running alongside APHA statutory testing. Carefully selected high risk cattle are being Actiphage-tested in addition to the standard skin testing, Gamma Interferon and ELISA blood testing being performed by APHA. This has enabled the detection of M. Bovis in cattle that have tested clear by all other testing methods.

Vet Robert Price-Jones says: “There remains a need for an accurate blood test that detects M. bovis directly, rather than relying on immunological methods of detection.

“The trial’s initial results indicate that Actiphage has a high sensitivity and specificity with nearly 60% of our ‘high risk’ group of animals testing positive. All of these high risk animals had recently tested clear to the conventional skin test and Gamma Interferon tests in the two weeks prior to testing with Actiphage. A small number of the Actiphage-positive animals later tested positive to an ELISA antibody test.

“The trial is ongoing yet our initial results suggest Actiphage will detect animals harbouring M. bovis that conventional testing is failing to detect.”

Inaugural AberTB Conference

The inaugural one-day conference aims to provide delegates with a greater understanding of current tests and their limitations and to give a forward look at new tests that are on the horizon.

The keynote speech will be given by Professor Christianne Glossop, Chief Veterinary Officer for Wales, who will provide an update on progress with bTB eradication in Wales. Other speakers from the fields of scientific research, veterinary science, agriculture and government will discuss the immunology of the disease, detection of mycobacteria and how to optimise testing.

The summary will be given by Welsh Dairy Farmer Abi Reader, founder of #CowsOnTour.

AberTB is being held at the Medrus Conference Centre, Penbryn Halls of Residence, Aberystwyth University SY23 3BY on 17 September.

Further details are available on the AberTB Conference page.

See Lesley Griffiths’ comments here.

Share:
  • Bovine TB, Events

Related posts

Loading...
See PBD Biotech at The Dairy Show

5 October 2022

See us at The Dairy Show

September 6, 2022
Ensuring consumer confidence in dairy products has never been more vital and we are delighted to have the opportunity to talk about our new blood test and bulk milk test with producers, cheesemakers, dairy companies and others across the industry...
See PBD Biotech at The Dairy Show

5 October 2022

See us at The Dairy Show

September 6, 2022
Ensuring consumer confidence in dairy products has never been more vital and we are delighted to have the opportunity to...
ICP 2022

12 -16th June 2022

ICP 2022

May 26, 2022
The role of Actiphage® as a powerful research tool for tuberculosis-related diseases is to be explored at the 15th International Association for Paratuberculosis Colloquium (ICP2022) in Dublin on 12 – 16th June 2022.
ICP 2022

12 -16th June 2022

ICP 2022

May 26, 2022
The role of Actiphage® as a powerful research tool for tuberculosis-related diseases is to be explored at the 15th International...
Cath Rees

21-23 August 2022

The Science of Artisan Cheese

May 25, 2022
Prof. Cath Rees CSO has spoken at the conference on several occasions and is delighted to be invited back to talk about developments in Actiphage, and its application to test milk for the presence of bTB and MAP.
Cath Rees

21-23 August 2022

The Science of Artisan Cheese

May 25, 2022
Prof. Cath Rees CSO has spoken at the conference on several occasions and is delighted to be invited back to...
ECCMID conference

23-26 April 2022

Novel TB diagnostics paper to be presented at ECCMID 2022

April 4, 2022
Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session at ECCMID 2022
ECCMID conference

23-26 April 2022

Novel TB diagnostics paper to be presented at ECCMID 2022

April 4, 2022
Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session...
1 2 … 8 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More